This is a concise overview. Switch to Full evaluation (Detailed) above for the complete report.
Problem
Add Kaplan–Meier survival curves with at-risk tables for the primary outcome; include landmark analyses at 48h and day 7.
Survival curves are standard for BSI mortality studies and are expected by infectious disease journal reviewers; their absence is the most conspicuous methodological omission.
Suggested fix
Add Kaplan–Meier survival curves with at-risk tables for the primary outcome; include landmark analyses at 48h and day 7.
Problem
Compare timing thresholds against Surviving Sepsis Campaign 2021 criteria; justify any deviations with cited validation evidence.
The novel pathogen-specific timing definition is the most methodologically innovative aspect of the study but is currently underexplained; alignment with international guidelines is essential for generalisability claims.
Suggested fix
Compare timing thresholds against Surviving Sepsis Campaign 2021 criteria; justify any deviations with cited validation evidence.
Problem
Report sample size calculation, explicitly acknowledge underpowering for subgroup analyses, and label combination therapy finding as exploratory.
Transparency about statistical power is expected and reduces the risk of overinterpretation of subgroup findings by downstream clinical readers.
Suggested fix
Report sample size calculation, explicitly acknowledge underpowering for subgroup analyses, and label combination therapy finding as exploratory.
Quick win: The primary finding (appropriate therapy reduces mortality threefold) is robust and clinically significant. The main revisions are presentation-level: add survival curves, contextualise the timing definition against guidelines, and clearly label secondary findings as exploratory. These changes are achievable without new data collection.
